Posted by Michael Wonder on 28 Oct 2022
Outlook Therapeutics announces acceptance of biologics license application by U.S. FDA for ONS-5010 as a treatment for wet AMD
28 October 2022 - Prescription Drug User Fee Act goal date of 29 August 2023.
Outlook Therapeutics today announced that the US FDA has accepted for filing a biologics license application for ONS-5010 Lytenava (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration.
